HHS is sending tests to large commercial labs while other labs are prepping assays as part of what some suggest is a more coordinated response than that to COVID-19.
The test measures changes in wavelength to quantify the presence of disease in a patient sample in about 40 minutes.
Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus.
Illumina Acquires IDbyDNA
The firms have had an alliance for the past two years and market a respiratory pathogen panel.
Cue Health to Lay Off 170 People
The firm said it was laying off staff due to economic challenges and the US government's decision to reduce funding for COVID-19 testing.
The new assay makes a number of modifications to enhance the sensitivity of the CRISPR reaction and allow detection of rare targets.
Branded InSignia, the patented technology will first be incorporated into a gonorrhea antimicrobial susceptibility assay, followed by a point-of-care test.